Navigation Links
Quark Pharmaceuticals to Present at the 20th Annual Piper Jaffray Health Care Conference
Date:12/1/2008

Presentation to Highlight Results of Ocular Neuroprotection Candidate

FREMONT, Calif., Dec. 1 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced that its Chief Operating Officer, Dr. Rami Skaliter is scheduled to present results on the Company's ocular neuroprotection candidate at the 20th Annual Piper Jaffray Health Care Conference to be held December 2-3, 2008 at the New York Palace in New York City.

                       Event: 20th Annual Piper Jaffray Health Care Conference
                       Date:  Tuesday, December 2, 2008
                       Time:  11:30 am ET

As previously announced, the ocular neuroprotection candidate is the Company's first RNAi drug candidate having a novel, proprietary structure covered by Quark's intellectual property. Data has validated its neuroprotective effects on dying retinal ganglion cells, a cause of blindness and glaucoma.

About Quark Pharmaceuticals, Inc.

Quark Pharmaceuticals, Inc. is a development-stage pharmaceutical company engaged in discovering and developing novel therapeutic RNAi drug candidates. Quark has a fully integrated drug development platform that spans therapeutic target identification to drug development. Quark's RNAi technology includes novel siRNA structures and chemistry providing Quark with freedom to operate in the siRNA intellectual property arena, as well as the ability for non-invasive delivery of siRNA to target tissues including the eye, ear, kidney, lung, spinal cord and brain.

PF-4523655 (RTP801i-14), currently in Phase II clinical trials, is a synthetic, chemically modified, siRNA molecule to inhibit the expression of the gene RTP801 discovered by Quark through the gene discovery platform BiFAR. PF-4523655 is licensed to Pf
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Quark Pharmaceuticals Receives FDA Approval of IND for Kidney Transplant siRNA Drug DGFi
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
7. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
9. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
10. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
11. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 2014 Insuranceservicecompany.com has released a new ... an investment tool. , Whole life insurance can provide ... be used as an investment tool. Clients can save money ... account. , A whole life insurance plan features a ... In order for this policy to be profitable, clients should ...
(Date:9/16/2014)... is partly caused by lapses in a very specific ... of Waterloo study. , The study, published in ... first to conclusively link reduced operation of the dorsolateral ... , "It has long been thought that the dorsolateral ... in check," said Professor Peter Hall, senior author on ...
(Date:9/16/2014)... Acute Cardiovascular Care 2014 is the event of the ... is the annual meeting of the Acute Cardiovascular Care ... and takes place 18-20 October in Geneva, Switzerland. ... Acute cardiovascular care is the specialty of cardiology dealing ... heart attack, cardiac arrest, and acute heart failure. The ...
(Date:9/16/2014)... is available in French . ... by pediatricians and researchers at Sainte-Justine University Hospital Research ... the prestigious medical journal Nature Medicine on ... migrates to the nucleus of nerve cells in the ... opens the possibility of developing new, more selective drugs ...
(Date:9/16/2014)... Dairy is considered ... daily consumption of 2-4 portions of milk-based products such as ... well known that dairy products contain calcium and minerals good ... may also have beneficial effects on metabolic health and can ... 2 diabetes. , Curious about these impacts, researchers from ...
Breaking Medicine News(10 mins):Health News:Whole Life Insurance Can Be A Good Investment Tool for Retirement! 2Health News:Caving to cravings? Indulging in junk food linked to lapses in brain function 2Health News:ACCA congress: Ensuring a rapid response to cardiac emergencies 2Health News:ACCA congress: Ensuring a rapid response to cardiac emergencies 3Health News:More cheese, please! News study shows dairy is good for your metabolic health 2
... men after bypass surgery, according to a new study done ... say whether the //results are due to medical or psychosocial ... outcomes after bypass surgery than men. Most have attributed this ... generally older, sicker, and have fewer social supports. In this ...
... is when symptoms have lasted for less than three ... self-management program that includes group classes, exercise sheet handouts, ... manage their back pain. ,Researchers from Indiana University ... low back pain. The program focuses on boosting confidence ...
... study shows hydrotherapy, or water exercise, may improve strength and ... studied more than 100 patients with osteoarthritis who were older ... first group exercised three times a week in a swimming ... did not exercise at all. Both the water and gym ...
... may improve strength and mobility in patients with osteoarthritis.// ... who were older than age 50. Patients were divided into ... in a swimming pool, the second exercised in a gym, ... water and gym programs focused on resistance exercises. ,Results ...
... lasted for less than three months. ,A new study ... sheet// handouts, and telephone follow-up calls may help patients ... from Indiana University developed a self-management program for poor, ... on boosting confidence in order to increase their motivation ...
... reducing the signs of aging in the neck. The procedure involves ... reduce the saggy appearance of the neck. Researchers say this new ... are often changes in the neck and face including the loss ... of fat in the neck. This causes the skin to sag. ...
Cached Medicine News:
(Date:9/16/2014)... , Sept. 16, 2014 Surgeons at The ... in a case report the first successful use of ... 13- year-old boy with failing Fontan circulation to bridge ... was 3 years old, the patient received a Fontan ... functional single ventricle. "The Fontan operation is the final ...
(Date:9/16/2014)... 16, 2014  Formex, LLC ("Formex"), a ... Mr. Greg Weilersbacher joined Formex as Director of ... Greg Weilersbacher has over ... expertise in Quality Assurance, Facility Validation, GMP ... brings to Formex a diverse wealth of ...
(Date:9/16/2014)...   Evana Automation Specialists , a leading Systems ... systems, recently received a contract to provide a robotic ... Evana solution will help error-proof the process of assembling ... reduce labor. A catheter adapter, connector ... cell. The robot will pick the adapter, connector and ...
Breaking Medicine Technology:13-Year-Old Boy with Failed Fontan Circulation Bridged to Transplant Using the SynCardia Total Artificial Heart, Published in Annals of Thoracic Surgery 213-Year-Old Boy with Failed Fontan Circulation Bridged to Transplant Using the SynCardia Total Artificial Heart, Published in Annals of Thoracic Surgery 3Greg Weilersbacher Joins Formex, LLC As Director of Quality Assurance and Quality Control 2Evana Automation to Supply Robotic Assembly Cell to Leading Medical Device Manufacturer 2Evana Automation to Supply Robotic Assembly Cell to Leading Medical Device Manufacturer 3
... VIVUS, Inc. (Nasdaq: VVUS ) announced today ... the U.S. Food and Drug Administration (FDA) regarding its ... QNEXA® (phentermine/topiramate) Controlled-Release Capsules. The FDA issued the CRL ... approved in its present form.  The application seeks the ...
... Corporation (Nasdaq: THOR ), a world leader ... and restore failing hearts, said revenues from continuing operations ... versus the third quarter of 2009. Results ... first nine months of 2010 and 2009 exclude contributions ...
Cached Medicine Technology:FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA® 2FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA® 3FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA® 4FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA® 5Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 2Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 3Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 4Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 5Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 6Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 7Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 8Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 9Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 10Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 11Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 12Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 13Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 14Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 15Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 16
Inquire...
... Roches patented polymerase chain reaction (PCR) ... technology, is an essential component of Roches ... PCR allows minute amounts of selected unique ... into billions of copies (that is, to ...
... Introducing BenchMark XT® the only fully ... flexibility you need to expand your ... improve your slide turnaround time. All ... choose how to use the BenchMark ...
... Reicherts new ATP Auto Non-Contact Tonometer / ... / pachymeter, combining the measurement of IOP ... response to numerous clinical studies that have ... thickness as well as intraocular pressure in ...
Medicine Products: